Zynerba Pharmaceuticals Inc. (ZYNE) Stock Price Up 4.3%
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)’s share price rose 4.3% on Thursday . The stock traded as high as $7.79 and last traded at $7.72, with a volume of 103,664 shares changing hands. The stock had previously closed at $7.40.
ZYNE has been the subject of several analyst reports. Jefferies Group restated a “buy” rating and issued a $32.00 price objective on shares of Zynerba Pharmaceuticals in a report on Thursday, April 7th. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $29.00 target price on shares of Zynerba Pharmaceuticals in a research note on Tuesday, June 28th. Canaccord Genuity reiterated a “buy” rating on shares of Zynerba Pharmaceuticals in a research note on Monday, April 18th. Finally, Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 18th. Six research analysts have rated the stock with a buy rating, Zynerba Pharmaceuticals has an average rating of “Buy” and a consensus price target of $28.58.
The company’s market capitalization is $68.81 million. The stock has a 50 day moving average of $7.82 and a 200 day moving average of $8.13.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.07. Analysts anticipate that Zynerba Pharmaceuticals Inc. will post ($2.37) EPS for the current fiscal year.
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.